Replimune’s resubmitted BLA for oncolytic virus RP1 (vusolimogene oderparepvec) + nivolumab in advanced melanoma was accepted for review in October, then rejected again via a second complete response letter—despite IGNYTE (n=140) showing a 34% response rate and median duration of response of 24.8 months.

Why It Matters To Oncology

• FDA’s central critique: IGNYTE wasn’t designed to isolate RP1’s contribution when combined with nivolumab, and population heterogeneity made the response rate hard to interpret—core issues for combo-development and single-arm accelerated approval strategies.

• The case spotlights a recurring regulatory fault line in immuno-oncology: promising single-arm response signals (even with durable DoR) may not clear the “substantial evidence” bar without a design that supports attribution of effect.

• Replimune argues FDA feedback shifted across meetings (Type B, pre-BLA, Type A), raising operational risk for sponsors building registrational packages around evolving expectations.

The Financials

• Shares fell ~20% on the news, with an additional ~60% drop after hours.

• CEO Sushil Patel said that “without timely accelerated approval, the development of RP1 will not be viable,” signaling potential program retrenchment.

• Company indicated looming job cuts and a major scale-back of US manufacturing operations.

What They're Saying

• Replimune: Patients won’t get “a treatment desperately needed… Not because the medicine failed. Because the system did,” calling the review “fragmented and slow-moving” with “inconsistent communication.”

• Company claims reviewer turnover occurred between the initial and resubmitted BLA, and says a senior prior reviewer publicly indicated the clinical team felt evidence was adequate but “leadership did not agree.”

• FDA (per CRL): Concerns about IGNYTE design were “clearly communicated” in multiple interactions; added analyses and early Phase III data were “insufficient to support an efficacy claim,” and adequate well-controlled trial(s) are needed.

What's Next

• Regulatory path likely hinges on results from IGNYTE-3 (confirmatory Phase III) or another trial capable of attributing benefit to RP1 beyond anti–PD-1 alone.

• Expect broader read-through for oncolytic virus and IO-combo developers: pre-specifying attribution strategies, managing heterogeneity, and pressure-testing single-arm registrational plans against evolving FDA standards.

• Operationally, Replimune’s stated viability concerns suggest near-term prioritization decisions across pipeline, manufacturing footprint, and spend while the confirmatory strategy matures.